SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction driven by anticipation for the upcoming 4/20 cultural event, with its community actively promoting it as a Solana-based crypto for global cannabis legalization, often touting it as 'like Bitcoin but way higher' for its purpose and vibes. Despite some voicing concerns about its volatility and 'pump and dump' nature, proponents emphasize its steady, culture-first approach and long-term potential within the evolving cannabis market.

OpenAI pioneers large-language models like GPT and DALL·E, enabling advanced AI applications. Their research emphasizes both cutting-edge capability and responsible deployment strategies.

OpenAI PreStocks

The symbol OPENAI CRYPTO, labeled 'OpenAI PreStocks,' is trending amid strong community skepticism regarding its legitimacy, with many users actively discussing whether it's a scam crypto token unrelated to the well-known AI company and questioning its presence on the platform.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending following its recent listing on Coinbase, with the community actively accumulating the token during market dips, seeing it as an undervalued utility play in the real-time payroll and payment sector. Discussion is also driven by forthcoming updates to its Super App, new partnerships, and its ISO 20022 and MiCA compliance, positioning it as a strong contender against established giants like XRP.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amidst escalating speculation of a potential buyout from major tech players like SpaceX or Amazon, leveraging its uniquely valuable n53 spectrum and deepening Apple partnership. The community is eagerly anticipating key FCC decisions regarding spectrum use and the deployment of Globalstar's C-3 constellation, seen as critical catalysts.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Spruce Biosciences (SPRB) is trending after receiving FDA Breakthrough Therapy Designation for its tralesinidase alfa therapy targeting Sanfilippo Syndrome Type B, a rare genetic disorder. This news, coupled with the stock's low float, has ignited speculative trading and high price targets from analysts, though some community members are debating its long-term valuation in light of recent dilution and the drug's niche market.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express is trending after its Q4 earnings showcased robust revenue and an increased dividend, with positive guidance for the upcoming year, despite increased expenses. The market is also actively debating a proposed credit card interest rate cap, with many viewing AXP's affluent customer base as a key factor in its resilience against broader sector concerns.

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health Inc

Elevance Health is trending as investors digest its recent earnings, where an adjusted EPS beat was tempered by a cautious 2026 guidance, sparking debate about its impact amid broader healthcare sector concerns. Community chatter highlights regulatory uncertainties and rising costs, leading to a split between those selling off and others seeing a potential buying opportunity.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending due to reaffirmed FY25 outlook and robust VEVYE script trends, bolstered by CVS Caremark Tier 1 formulary status. The community actively anticipates a potential short squeeze and accelerated growth, further fueled by a Deloitte audit upgrade signaling big-cap ambitions within the ophthalmic sector.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending amidst a broader crypto market downturn, fueling a stark divide where long-term holders are aggressively buying the dip, citing its strong fundamentals and "digital silver" status, while frustrated bears emphasize its consistent underperformance and predict further price declines. Community discussions frequently center on speculation that "whales" are orchestrating market moves to accumulate undervalued assets.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom Inc. is trending amid a mixed sentiment, as robust preliminary revenue and an AI-driven Stelo platform upgrade are overshadowed by ongoing community concerns regarding recent FDA Class 1 recalls for its G7 device, product reliability, and potential class-action lawsuits.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intellia Therapeutics, Inc. $NTLA Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 68.0% during the third quarter, according to the company in its most recent 13F...

Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of -5.26% and -0.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6% - Time to Sell?

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.6% - Here's Why...

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold

Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

<ul class="summary-bullets"><li>The trial is for the use of Nexiguran Ziclumeran (Nex-Z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare nerve-damaging disease.</li><li>The Phase 3 trial was suspended after a patient dosed with Nex-Z in a related trial experienced a severe liver enzyme issue.</li><li>The decision clears the way for Intellia to resume patient enrollment in the study.</li></ul>Shares of Intellia Therapeutics (NTLA) gained more than 13% on Tuesday morning as the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial of Nexiguran Ziclumeran (Nex-Z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare nerve-damaging disease.A clinical hold is a delay or suspension of an ongoing clinical trial due to serious safety concerns.<h2 class="st-heading-2">Why Did FDA Suspend The Trial?</h2>The clinical hold was imposed in late October 2025 after a patient dosed with Nex-Z in a related trial experienced a severe liver enzyme issue that met the protocol-defined pausing criteria. Since then, Intellia has worked with the FDA to implement study modifications, including enhanced monitoring of liver-related lab tests.“With the clinical hold for MAGNITUDE-2 lifted, our team is focused on resuming patient enrollment as quickly as possible as we seek to advance this potential one-time treatment option for people living with ATTRv-PN,” said John Leonard, Intellia’s President and CEO.MAGNITUDE-2 is a randomized placebo-controlled study assessing the safety and effectiveness of Nex-Z in patients with ATTRv-PN. Following a protocol update, Intellia increased target enrollment to about 60 patients.<h2 class="st-heading-2">What’s Next?</h2>The decision clears the way for Intellia to resume patient enrollment in the study. Intellia said discussions with the FDA are ongoing regarding the separate MAGNITUDE Phase 3 trial of Nex-Z in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and the company will provide an update once a path forward is finalized.Nex-Z is a gene-editing therapy designed to permanently inactivate the TTR gene, which is key in producing a protein called transthyretin. The program has received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, highlighting its potential to address serious unmet medical needs.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘high’ message volumes. <a href="https://stocktwits.com/symbol/NTLA">NTLA</a> was among the top trending tickers on the platform at the time of writing.One user believes the development should be good for the sector.<stembedurl>https://stocktwits.com/FredGS/message/642984565</stembedurl>Another user expects the stock to cross $20 by the end of the trading session. It is currently trading close to $15.<stembedurl>https://stocktwits.com/BrokersNY/message/642985076</stembedurl>The stock has gained nearly 50% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/what-triggered-qbts-stock-s-pre-market-rally-today/cmyaCXDR4LL">What Triggered QBTS Stock’s Pre-Market Rally Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About?

The U.S. Food and Drug Administration lifted the clinical hold on a Phase 3 Trial, which was imposed on October 29, 2025 following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient dosed with Nex-Z 

Equity

AI Hits the Factory Floor, Defense Wins Get Bigger, and Gene Editing Regains Momentum

This morning’s news flow highlights how innovation is translating into execution across robotics, industrial automation, defense, and life sciences.

Intellia Therapeutics (NASDAQ:NTLA) Shares Up 7.9% - Time to Buy?

Intellia Therapeutics (NASDAQ:NTLA) Trading Up 7.9% - Still a Buy...

Intellia Therapeutics (NASDAQ:NTLA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Intellia Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Sumitomo Mitsui Trust Group Inc. Sells 316,409 Shares of Intellia Therapeutics, Inc. $NTLA

Sumitomo Mitsui Trust Group Inc. decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 11.8% in the 3rd quarter, according to the company in its most recent 13F filing...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

NTLA
Intellia Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NTLA News

NTLAIntellia Therapeutics Inc